Rani Therapeutics Holdings Management
Management criteria checks 3/4
Rani Therapeutics Holdings' CEO is Talat Imran, appointed in Jun 2021, has a tenure of 3.92 years. total yearly compensation is $3.04M, comprised of 3.5% salary and 96.5% bonuses, including company stock and options. directly owns 0.85% of the company’s shares, worth $315.74K. The average tenure of the management team and the board of directors is 3.9 years and 5.4 years respectively.
Key information
Talat Imran
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 3.48% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Feb 07
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Jul 16Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Mar 20Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Aug 08We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Feb 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$30m |
| Dec 31 2024 | US$3m | US$106k | -US$30m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$31m |
| Mar 31 2024 | n/a | n/a | -US$33m |
| Dec 31 2023 | US$5m | US$450k | -US$34m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$34m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$4m | US$515k | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$12m | US$408k | -US$8m |
Compensation vs Market: Talat's total compensation ($USD3.04M) is above average for companies of similar size in the US market ($USD645.80K).
Compensation vs Earnings: Talat's compensation has been consistent with company performance over the past year.
CEO
Talat Imran (42 yo)
Mr. Talat Imran serves as an Investment Professional at VHM Ventures. He has served as Chief Executive Officer and Director of Rani Therapeutics Holdings, Inc. since June 2021 and served as its Vice Presid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$223.25k | 0.023% $ 8.6k | |
| CEO & Director | 3.9yrs | US$3.04m | 0.85% $ 315.7k | |
| Chief Financial Officer | 6.5yrs | US$1.29m | 0.53% $ 195.9k | |
| Chief Scientific Officer | 11.9yrs | US$1.29m | 0.57% $ 211.1k | |
| Vice President of Technical Operations | less than a year | no data | no data | |
| General Counsel | 3.8yrs | no data | no data | |
| Vice President of Human Resources | 4.3yrs | no data | no data | |
| Chief Business Officer | 2yrs | no data | 0.054% $ 20.0k | |
| Vice President of Clinical Development | no data | no data | no data |
Experienced Management: RANI's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$223.25k | 0.023% $ 8.6k | |
| CEO & Director | 3.9yrs | US$3.04m | 0.85% $ 315.7k | |
| Independent Director | 4.1yrs | US$214.50k | 0.15% $ 56.1k | |
| Independent Director | 6.7yrs | US$207.75k | 0.81% $ 302.4k | |
| Director | 12.9yrs | US$205.75k | 0% $ 0 | |
| Independent Director | 8.9yrs | US$217.00k | 0.034% $ 12.8k | |
| Independent Director | 3.3yrs | US$208.36k | 0.65% $ 240.6k |
Experienced Board: RANI's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 00:37 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rani Therapeutics Holdings, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |